Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 840-846

  McDonnell, Alison M ^a,b   Currie, Andrew J ^a,c   Brown, Matthew ^b   Kania, Kasia ^a,b   Wylie, Ben ^a,b   Cleaver, Amanda ^a,b   Lake, Richard ^a,b   Robinson, Bruce W S ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

Cross presentation; Cytotoxic T cell; Dendritic cells; Lymph nodes; Tumor

Indexed keywords

TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL; CANCER LOCALIZATION; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; LYMPH NODE; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84886944060     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20493     Document Type: Article

References (53)

1. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411:1058-64; PMID:11429607; http://dx.doi.org/10.1038/35082583.
2. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol 2010; 10:403- 14; PMID:20498667; http://dx.doi.org/10.1038/nri2780.
3. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999; 162:5838-45; PMID:10229818.
4. Robinson BW, Lake RA, Nelson DJ, Scott BA, Marzo AL. Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation. Immunol Cell Biol 1999; 77:552-8; PMID:10571677; http://dx.doi.org/10.1046/j.1440-711.1999.00876.x.
5. + CTL to cause tumor eradication. J Immunol 2004; 173:6753-9; PMID:15557168.
6. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006; 25:153-62; PMID:16860764; http://dx.doi.org/10.1016/j.immuni.2006.04.017.
7. - but not plasmacytoid dendritic cells. J Exp Med 2008; 205:1621-34; PMID:18591406; http://dx.doi.org/10.1084/jem.20071365.
8. Martín-Fontecha A, Lanzavecchia A, Sallusto F. Dendritic cell migration to peripheral lymph nodes. Handb Exp Pharmacol 2009:31-49; http://dx.doi.org/10.1007/978-3-540-71029-5_2.
9. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pachéco Y, et al. Dendritic cells infiltrating human nonsmall cell lung cancer are blocked at immature stage. J Immunol 2007; 178:2763-9; PMID:17312119.
10. Preynat-Seauve O, Schuler P, Contassot E, Beermann F, Huard B, French LE. Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol 2006; 176:61-7; PMID:16365396.
11. Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, et al. Inefficient presentation of tumorderived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother 2008; 57:1665-73; PMID:18311487; http://dx.doi.org/10.1007/s00262-008-0487-4.
12. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998; 4:585-93; PMID:9533525.
13. Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002; 12:33-42; PMID:11926410; http://dx.doi.org/10.1006/scbi.2001.0400.
14. Gerner MY, Casey KA, Mescher MF. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol 2008; 181:155-64; PMID:18566380.
15. Gerner MY, Mescher MF. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol 2009; 182:2726-37; PMID:19234167; http://dx.doi.org/10.4049/jimmunol.0803479.
16. Ishida T, Oyama T, Carbone DP, Gabrilovich DI. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 1998; 161:4842- 51; PMID:9794417.
17. Lucas AD, Halliday GM. Progressor but not regressor skin tumours inhibit Langerhans' cell migration from epidermis to local lymph nodes. Immunology 1999; 97:130-7; PMID:10447724; http://dx.doi.org/10.1046/j.1365-2567.1999.00751.x.
18. Preynat-Seauve O, Contassot E, Schuler P, French LE, Huard B. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells. Melanoma Res 2007; 17:169-76; PMID:17505262; http://dx.doi.org/10.1097/CMR.0b013e3281844531.
19. Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med 2010; 16:98- 105; PMID:20037595; http://dx.doi.org/10.1038/nm.2074.
20. Carlson GW, Murray DR, Lyles RH, Staley CA, Hestley A, Cohen C. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 2003; 10:575- 81; PMID:12794026; http://dx.doi.org/10.1245/ASO.2003.03.054.
21. Gobardhan PD, Elias SG, Madsen EV, Bongers V, Ruitenberg HJ, Perre CI, et al. Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study. Ann Oncol 2009; 20:41-8; PMID:18653702; http://dx.doi.org/10.1093/annonc/mdn535.
22. Imoto S, Ochiai A, Okumura C, Wada N, Hasebe T. Impact of isolated tumor cells in sentinel lymph nodes detected by immunohistochemical staining. Eur J Surg Oncol 2006; 32:1175-9; PMID:16979316; http://dx.doi.org/10.1016/j.ejso.2006.08.006.
23. Rena O, Carsana L, Cristina S, Papalia E, Massera F, Errico L, et al. Lymph node isolated tumor cells and micrometastases in pathological stage I nonsmall cell lung cancer: prognostic significance. Eur J Cardiothorac Surg 2007; 32:863-7; PMID:17936004; http://dx.doi.org/10.1016/j.ejcts.2007.09.014.
24. Scheunemann P, Stoecklein NH, Hermann K, Rehders A, Eisenberger CF, Knoefel WT, et al. Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance. Langenbecks Arch Surg 2009; 394:105-13; PMID:18626657; http://dx.doi.org/10.1007/s00423-008-0369-4.
25. Graham DB, Stephenson LM, Lam SK, Brim K, Lee HM, Bautista J, et al. An ITAM-signaling pathway controls cross-presentation of particulate but not soluble antigens in dendritic cells. J Exp Med 2007; 204:2889-97; PMID:17984307; http://dx.doi.org/10.1084/jem.20071283.
26. Hargadon KM, Brinkman CC, Sheasley-O'neill SL, Nichols LA, Bullock TNJ, Engelhard VH. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. J Immunol 2006; 177:6081-90; PMID:17056534.
27. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999; 96:2233- 8; PMID:10051624; http://dx.doi.org/10.1073/pnas.96.5.2233.
28. + T cell responses. J Immunol 2001; 167:3577-84; PMID:11564769.
29. Straten P, Dahl C, Schrama D, Pedersen LO, Andersen MH, Seremet T, et al. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. Cancer Immunol Immunother 2006; 55:495-502; PMID:16001163; http://dx.doi.org/10.1007/s00262-005-0023-8.
30. + T cells. J Exp Med 2003; 197:985- 95; PMID:12695490; http://dx.doi.org/10.1084/jem.20021804.
31. Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, et al. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 2003; 63:9007-15; PMID:14695219.
32. Preynat-Seauve O, Contassot E, Schuler P, Piguet V, French LE, Huard B. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Cancer Res 2007; 67:5009-16; PMID:17510433; http://dx.doi.org/10.1158/0008-5472.CAN-06-4494.
33. Bai XF, Gao JX, Liu J, Wen J, Zheng P, Liu Y. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res 2001; 61:6860-7; PMID:11559562.
34. Boonman ZFHM, van Mierlo GJD, Fransen MF, Franken KLMC, Offringa R, Melief CJM, et al. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction. J Immunol 2004; 172:1567-74; PMID:14734736.
35. + DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur J Immunol 2010; 40:1617- 27; PMID:20373290; http://dx.doi.org/10.1002/eji.200940153.
36. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumorspecific CD8 T cells. J Immunol 2003; 170:4905-13; PMID:12734333.
37. Zinkernagel RM. On cross-priming of MHC class I-specific CTL: rule or exception? Eur J Immunol 2002; 32:2385-92; PMID:12207322; http://dx.doi.org/10.1002/1521-4141(200209)32:9<2385::AIDIMMU2385>3.0.CO;2-V.
38. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811; PMID:10837075; http://dx.doi.org/10.1146/annurev.immunol.18.1.767.
39. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711; PMID:12615891; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141040.
40. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007; 7:543-55; PMID:17589544; http://dx.doi.org/10.1038/nri2103.
41. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ 2008; 15:39-50; PMID:17948027; http://dx.doi.org/10.1038/sj.cdd.4402247.
42. Pinzon-Charry A, Maxwell T, López JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005; 83:451-61; PMID:16174093; http://dx.doi.org/10.1111/j.1440-711.2005.01371.x.
43. Boonman ZF, van Mierlo GJ, Fransen MF, de Keizer RJ, Jager MJ, Melief CJ, et al. Maintenance of immune tolerance depends on normal tissue homeostasis. J Immunol 2005; 175:4247-54; PMID:16177064.
44. Kruck S, Gakis G, Stenzl A. Disseminated and circulating tumor cells for monitoring chemotherapy in urological tumors. Anticancer Res 2011; 31:2053-7; PMID:21737622.
45. Lianidou ES, Markou A. Circulating tumor cells as emerging tumor biomarkers in breast cancer. Clin Chem Lab Med 2011, 49:1579-90; PMID:21801030; http://dx.doi.org/10.1515/CCLM.2011.628.
46. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization and future challenges. Clin Chem 2011; 57:1242-55; PMID:21784769; http://dx.doi.org/10.1373/clinchem.2011.165068.
47. Paterlini-Bréchot P. Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis- capable malignancy. Future Oncol 2011; 7:849- 71; PMID:21732757; http://dx.doi.org/10.2217/fon.11.32.
48. Clobes H, Fossâ SD, Waehre H, Jocham D, Berner A. The immunohistochemical assessment of occult regional lymph node metastases in patients with T3pN0M0 prostate cancer before definitive radiotherapy. BJU Int 2000; 85:270-5; PMID:10671880; http://dx.doi.org/10.1046/j.1464-410x.2000.00406.x.
49. Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med 2008; 359:2814-23; PMID:19109576; http://dx.doi.org/10.1056/NEJMra0805239. 50. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006; 127:679-95; PMID:17110329; http://dx.doi.org/10.1016/j.cell.2006.11.001.
50. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006; 127:679-95; PMID:17110329; http://dx.doi.org/10.1016/j.cell.2006.11.001
51. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999; 59:1071-9; PMID:10070965.
52. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994; 171:131-7; PMID:8176234; http://dx.doi.org/10.1016/0022-1759(94)90236-4.
53. Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 1998; 161:5338-46; PMID:9820507.